Effect of Nilotinib in Cerebellar Ataxia Patients

Status Completed

Clinical Trial Summary

This is an institutional cohort study. Patients confirmed with spinocerebellar ataxia (SCA) and taking or planning to take Nilotinib (Tasigna®) are enrolled in this study. The daily dose of Nilotinib is 150mg-300mg and the patients will be followed up at 1, 3, 6, and 12 months. Rating scale for Friedreich's ataxia I and II and Barthel index are used as general function and daily living performance index. Scale for assessment and rating of ataxia (SARA) are used as an objective measure of cerebellar function. Adverse drug reactions are evaluated based on CTCAE version 4.0.

Clinical Trial Description

1. Patients taking Nilotinib 1-1.Baseline information: demographics, genetic type of SCA, brain MRI, electrocardiography, routine blood evaluations 1-2. Time point of evaluation: At initiation of taking Nilotinib, 1, 3, 6, and 12 months 1-3. Evaluation items (at each time point) Routine check-up: electrocardiography, routine blood evaluations Adverse events: CTCAE version 4.0 Daily living performance: Barthel index General function: Friedreich's ataxia I and II 1-4. Change of drug dose Based on the attending physician's decision 2. Patients planning to take Nilotinib 2-1.Baseline information: demographics, genetic type of SCA, brain MRI, electrocardiography, routine blood evaluations 2-2. Time point of evaluation: Baseline, 1, 3, 6, and 12 months 2-3. Evaluation items (at each time point) Routine check-up: electrocardiography, routine blood evaluations Adverse events: CTCAE version 4.0 Cerebellar function: Scale for assessment and rating of ataxia (SARA) Daily living performance: Barthel index General function: Friedreich's ataxia I and II 2-4. Change of drug dose Based on the attending physician's decision ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03932669
Study type	Interventional
Source	Seoul National University Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	November 19, 2018
Completion date	August 13, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03703830` - tDCS Associated With Locomotor Training on Functional Mobility of Cerebellar Ataxia	N/A
Completed	`NCT04937725` - Reading Problems Associated With Central Nervous System (CNS) Pathologies.
Completed	`NCT03120013` - Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia	N/A
Recruiting	`NCT04830904` - Efficacy of Lycra Garments in Ataxic Subjects	N/A
Not yet recruiting	`NCT04297540` - Neuromodulation of Social Skills in Childhood Ataxia	N/A
Terminated	`NCT03901638` - Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy	Phase 3
Recruiting	`NCT03624374` - Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)